Hansoh Pharma's HS-20093 in Combination Therapy Receives Breakthrough Therapy Designation

On April 16, Hansoh Pharma (03692) announced that its self-developed B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 for injection, in combination with adebrelimab, has been approved by the National Medical Products Administration (NMPA) of China for inclusion in the breakthrough therapy designation. The proposed indication is for locally advanced or metastatic non-squamous non-small cell lung cancer that is driver gene-negative and has progressed or relapsed after previous platinum-based chemotherapy.